Velaglucerase Alfa

Summary

Velaglucerase Alfa (CHEMBL1201865) is an approved enzyme (ATC A16AB10); indicated across 1 condition including gaucher disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: A16AB10
• Indications: 1 condition
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201865
Name	Velaglucerase Alfa
Type	Enzyme
Max phase	4
ATC	A16AB10

Also known as: EC 3.2.1.45, EC-3.2.1.45, Ga-gcb, Gagcb, Velaglucerasa alfa, Velaglucerase alfa, Vpriv, VELAGLUCERASE ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
Gaucher disease	4	MONDO:0018150	MONDO:0018150

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	4
PHASE1/PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02528617	PHASE4	WITHDRAWN	The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
NCT02574286	PHASE4	COMPLETED	Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
NCT03702361	PHASE4	COMPLETED	Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
NCT04120506	PHASE4	COMPLETED	Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)
NCT00553631	PHASE3	COMPLETED	Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
NCT01614574	PHASE3	COMPLETED	Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
NCT01842841	PHASE3	COMPLETED	Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
NCT05529992	PHASE3	COMPLETED	A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
NCT00391625	PHASE1/PHASE2	COMPLETED	Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
NCT01685216	PHASE1/PHASE2	COMPLETED	Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
NCT00954460	Not specified	APPROVED_FOR_MARKETING	Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).